Granmed Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 20-12-2024
- Paid Up Capital ₹ 0.10 M
as on 20-12-2024
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.43 Cr
as on 20-12-2024
- Revenue 26.62%
(FY 2022)
- Profit -21.02%
(FY 2022)
- Ebitda 79.69%
(FY 2022)
- Net Worth 92.41%
(FY 2022)
- Total Assets 26.37%
(FY 2022)
About Granmed Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.43 Cr.
Sunil Khurana, Navjeet Khurana, and Manju Khurana serve as directors at the Company.
- CIN/LLPIN
U24232HR2016PTC057764
- Company No.
057764
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jan 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Ambala, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Granmed Pharma Private Limited offer?
Granmed Pharma Private Limited offers a wide range of products and services, including Cardiovascular Drugs & Medication, Kidney Drugs.
Who are the key members and board of directors at Granmed Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Navjeet Khurana  | Director | 16-Jul-2019 | Current |
| Sunil Khurana | Director | 06-Jan-2016 | Current |
| Manju Khurana | Director | 16-Jul-2019 | Current |
Financial Performance of Granmed Pharma.
Granmed Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 26.62% increase. The company also saw a substantial fall in profitability, with a 21.02% decrease in profit. The company's net worth Soared by an impressive increase of 92.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Granmed Pharma?
Unlock access to Granmed Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Granmed Labs Private LimitedActive 3 years 3 monthsSunil Khurana and Navjeet Khurana are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 04 Oct 2024 | ₹2.28 M | Open |
Hdfc Bank Limited Creation Date: 03 Jun 2023 | ₹3.00 M | Open |
Hdfc Bank Limited Creation Date: 26 Jul 2021 | ₹7.00 M | Open |
How Many Employees Work at Granmed Pharma?
Unlock and access historical data on people associated with Granmed Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Granmed Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Granmed Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
